8-K: AI Technology Group Amends Merger Terms, Extends Closing

AI Technology Group Inc. has amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date and revising investment tranches due to financial audit obligations.

Summary

• The merger agreement between AI Technology Group Inc., AVM Biotechnology Inc., and Biomed 360 Solutions Corp. was amended on January 27, 2026.
• The closing date for the merger has been extended from March 31, 2026, to July 26, 2026.
• Investment obligations were updated due to longer merger timelines stemming from financial audit requirements.
• Tranche 1: $1,000,000 in loans confirmed as provided by August 1, 2025, by BioMed360, convertible into Parent Shares at $1.00 per share.
• Tranche 2: $1,000,000 confirmed as provided by November 20, 2025, by AVM Biotechnology Ltd., convertible into Parent Shares at $2.50 per share.
• Additional Tranche 2 investments of $1,000,000 each are scheduled for February 28, 2026, April 30, 2026, and June 30, 2026, convertible at $2.50 per share.
• Tranche 3: A minimum of $10,000,000 and a maximum of $25,000,000 is due on or before the Closing Date, convertible at $2.50 per share.
• Tranche 2 and 3 convertible loan amounts will accrue 10% per annum simple interest from the date received by AVM Biotechnology Inc., to be settled in shares at $2.50 per share at the Effective Time.
• A 30-day grace period applies to investment dates before a material breach is declared.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as moderately negative due to the significant delay in the merger closing date and the underlying reason of "Financial Audit obligations," which introduces uncertainty, despite the confirmation of prior investments and structured future funding.

Positives

• Confirmation of prior investment tranches ($1,000,000 by August 1, 2025, and $1,000,000 by November 20, 2025) indicates continued commitment to the merger.
• The structured investment tranches (Tranche 2 and 3) provide a clear financial roadmap for the merger, totaling a potential $13,000,000 to $28,000,000 in convertible loans.
• The 10% per annum simple interest on Tranche 2 and 3 loans provides a return for the lenders until conversion.

Negatives

• The merger closing date has been delayed by nearly four months, from March 31, 2026, to July 26, 2026.
• The delay is attributed to "longer merger timelines stemming from Financial Audit obligations," which could indicate complexities or issues in the audit process.
• The need for an amendment suggests that the original timeline and investment structure were not feasible, potentially raising questions about initial due diligence or planning.

Risks

• Merger Completion Risk: The extended timeline due to "Financial Audit obligations" introduces uncertainty and potential for further delays or even termination if audit issues are significant or cannot be resolved.
• Financial Audit Risk: The mention of "Financial Audit obligations" as the reason for delay suggests potential complexities or findings during the audit process that could impact the valuation or terms of the merger.
• Investment Commitment Risk: Failure to meet future investment increments (February 28, 2026, April 30, 2026, June 30, 2026, and Tranche 3) could constitute a material breach, jeopardizing the merger.
• Share Dilution Risk: The convertible loans (Tranche 1, 2, and 3) will result in the issuance of Parent Shares, potentially diluting existing shareholders.

Future Outlook

The merger is now expected to close by July 26, 2026, contingent on resolving financial audit obligations and the timely fulfillment of remaining investment tranches totaling between $13,000,000 and $28,000,000.

Industry Context

StockSavvy.ai notes that delays in merger timelines, particularly those attributed to financial audit obligations, are not uncommon in complex transactions involving emerging technology and biotechnology companies. Such delays often reflect the rigorous due diligence required to integrate diverse business models and ensure regulatory compliance, especially when dealing with convertible debt structures.

Comparison to Industry Standards

• The extension of a merger closing date due to audit complexities is a common occurrence, particularly in sectors like biotechnology and AI where intellectual property valuation and regulatory compliance can be intricate. For example, similar delays have been observed in biotech mergers such as the proposed acquisition of Medivation by Pfizer, which faced extended regulatory reviews, or in tech mergers like Broadcom's acquisition of VMware, which required extensive global regulatory approvals.
• The 10% simple interest on convertible loans is a reasonable rate for bridging finance in such a scenario, comparable to rates seen in venture debt or bridge financing for growth-stage companies.

Related Party Transactions

• The loans are provided by BioMed360 and AVM Biotechnology Ltd. (Merger Sub) on behalf of Parent, which are parties to the merger agreement, thus constituting related party transactions in the context of the merger.

Stakeholder Impact

• Shareholders: Potential for dilution from the conversion of Tranche 1, 2, and 3 loans into Parent Shares. Uncertainty due to merger delay and audit issues could impact share price.
• Creditors (Lenders): Will receive 10% simple interest on Tranche 2 and 3 loans, providing a return on their bridge financing.
• Employees: Uncertainty regarding the merger's completion and timeline could affect employee morale and retention, particularly for employees of the target companies.
• Management: Increased workload and scrutiny due to extended audit timelines and revised investment schedules.

Next Steps

• Investment of $1,000,000 (Tranche 2 increment) on or before February 28, 2026.
• Investment of $1,000,000 (Tranche 2 increment) on or before April 30, 2026.
• Investment of $1,000,000 (Tranche 2 increment) on or before June 30, 2026.
• Completion of financial audit obligations.
• Closing of the merger on or before July 26, 2026.
• Investment of Tranche 3 (minimum $10,000,000, maximum $25,000,000) on or before the Closing Date.

Key Dates

Recommendation

The extension of the merger closing date due to "Financial Audit obligations" introduces a notable level of uncertainty and potential risk, warranting a cautious approach. While the confirmed prior investments and structured future funding tranches demonstrate continued commitment, the delay itself, and the reason behind it, could signal underlying complexities that need to be resolved. Investors should hold and monitor the progress of the financial audit and the fulfillment of the revised investment schedule before making further investment decisions.

Keywords

AI Technology Group, AVM Biotechnology, Biomed 360 Solutions, Merger Agreement, 8-K Filing, Merger Amendment, Closing Date Extension, Convertible Loans, Investment Tranches, Financial Audit, Corporate Governance, SEC Filing, Biotechnology Merger, AI Company